Revenue rose 4.2 percent to 377.4 billion won, while net profit plunged 69.1 percent to 14 billion won, according to the preliminary consolidated figures.
Eppe, a once-weekly GLP-1 injection and the first obesity drug of its kind developed in South Korea, won approval from the Ministry of Food and Drug Safety on Oct. 7.
Hanmi shipped its first batches on Oct. 22, after the quarter had closed.
"We chose to see the return of the rights as a new starting point and decided to carry development through to the end with our own hands," said Kim Na-young, vice president at Hanmi during the drug's launch symposium in Seoul.
Revenue at Beijing Hanmi Pharmaceutical, the company's Chinese unit, slid 15.8 percent to 79.3 billion won after it began requiring payment before shipping over-the-counter products, the company said.
Hanmi's standalone operating profit climbed 9.7 percent, as standalone revenue rose 8.3 percent to 291.5 billion won on prescription drug sales.
Operating profit also tumbled from 131.1 billion won in the second quarter, when Hanmi booked a one-off upfront payment for licensing out Sonefpeglutide, a drug candidate for short bowel syndrome.
Research and development spending reached 62.3 billion won, or 16.5 percent of revenue.
Shares of Hanmi closed at 347,500 won per share, 1.42 percent lower than the day before.
AJP Takeaways
- Hanmi Pharmaceutical's operating profit for the July-September 2026 quarter fell 31.3 percent from a year earlier to 37.8 billion won, according to the company's preliminary filing on Oct. 27, 2026.
- Hanmi's revenue rose 4.2 percent to 377.4 billion won, while revenue at its Chinese unit, Beijing Hanmi Pharmaceutical, fell 15.8 percent to 79.3 billion won.
- Eppe, Hanmi's once-weekly GLP-1 obesity injection, won approval from South Korea’s Ministry of Food and Drug Safety on Oct. 7, 2026, and its first batches shipped on Oct. 22, 2026.
Copyright ⓒ Aju Press All rights reserved.
